Novotech Partners with Kyungpook National University Hospital to Strengthen Clinical Trial Capabilities in South Korea - Novotech

18 Mar 2025 11:26 PM

SEOUL, South Korea--BUSINESS WIRE--

Novotech, a global leading full-service clinical Contract Research Organization (CRO), and Acrostar, a provider of Site Management Organization (SMO) services have entered into a strategic partnership by signing a Memorandum of Understanding (MOU) with Kyungpook National University Hospital (KNUH). The partnership will support clinical trials across KNUH’s prestigious institutions including the Advanced Clinical Trials Center, the KNUH main campus, and the Chilgok KNUH in South Korea.

This collaboration is a key milestone for the advanced clinical trials in South Korea, strategically aligning with the amendments to the Advanced Regenerative Bio Act. This agreement builds upon the recent inauguration of KNUH’s Advanced Clinical Trials Center opened in November last year, marking its first official partnership post-amendment of the Bio Act.

The amendments to the Advanced Regenerative Bio Act expanded the scope of advanced regenerative medicine, allowing the use of investigational therapies in clinical trials and expanding the number of authorized regenerative medicine institutions. Previously limited to severe, rare, and incurable diseases, regenerative medicine applications will now extend to a broader range of conditions, including general diseases.

Patients outside of clinical trials will also gain access to regenerative medicine services, while the range of applicable technologies—including cell and gene therapies (CGT) and tissue engineering—has significantly expanded.

Under the previous framework, CGTs required formal drug approval for clinical application. With these regulatory changes, CGTs in clinical trials can now be utilized upon review committee approval, streamlining access to innovative therapies.

The partnership creates a comprehensive framework across KNUH’s network with early-stage clinical trials primarily conducted at the Advanced Clinical Trials Center, while late-stage trials will be managed with the KNUH’s hospital system itself.

Speaking at the ceremony, Prof. Hyungran Yoon, Director of the Advanced Clinical Trials Center, spoke about the benefits of the collaboration, “The Advanced Clinical Trials Center will oversee trials for all diseases treated at KNUH, strengthening our role as a leader in clinical research and regenerative medicine. The partnership agreement with Novotech will expand their capacity to offer innovative treatment opportunities both domestically and internationally.”

Dr. Yooni Kim, Managing Director, Asia-Pacific at Novotech, highlighted the strategic advantages. “This partnership combines Novotech’s global expertise with KNUH’s specialized capabilities to offer cutting-edge treatment solution and streamlined trial operations. By leveraging this synergy, we aim to boost South Korea’s position on the global stage in regenerative medicine and enhance clinical trial excellence worldwide.”

This partnership also marks a significant milestone for Acrostar, Novotech’s SMO services provider. Daniel Kim, Director of Acrostar Asia-Pacific, shared his excitement about the partnership, “This is Acrostar’s first partnership in South Korea. Through this collaboration, we will actively support the site and ensure the smooth progress of clinical trials from a site management perspective.”

This strategic partnership means a shared commitment to advancing clinical research in South Korea and contributing to the global development of regenerative medicine and advanced clinical trials.

About NovotechNovotech-CRO.com

Founded in 1997, Novotech is a global full-service clinical Contract Research Organization (CRO) focused on partnering with biotech and small to mid-size companies to accelerate the development of advanced and novel therapeutics at every phase.

Recognized for its industry-leading contributions, Novotech has received numerous prestigious awards, including the Fierce CRO 2024 Excellence Award in Clinical Trial Management and Global Operations, Frost & Sullivan 2024 Global Biotech CRO of the year award, Clinical Trials Arena 2024 Excellence Awards in Business Expansion, Innovation and Marketing, 2024 Employer of Choice, 2024 Great Place to Work in the US, 2024 Brandon Hall Gold Award, CRO Leadership Award 2023, the Asia Pacific Cell & Gene Therapy Clinical Trials Excellence 2023, the Asia-Pacific Contract Research Organization Company of the Year Award since 2006.

The Company offers a comprehensive suite of services including laboratories, Phase I facilities, drug development consulting, regulatory expertise, and has experience with over 5,000 clinical projects, including Phase I to Phase IV clinical trials and bioequivalence studies. With a presence in 34 office locations and a dedicated team of 3,000+ professionals worldwide, Novotech is a trusted end-to-end strategic partner of choice.

For more information or to speak to an expert team member visit www.Novotech-CRO.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20250317570511/en/

Contact details:

Media
Toyna Chin
[email protected]
USA: +1 415 364 8135

Images: